Changes in Hong Kong stocks | Two-way support for AI and innovative drugs, Jietai Technology-P (07666) rose more than 19% in early trading and continued to lead the AI pharmaceutical sector

The Zhitong Finance App learned that Jetai Technology-P (07666) continues to be sought after by market capital. It rose more than 19% in early trading today, continuing to lead the AI pharmaceutical sector. As of press release, it rose 11.87% to HK$12.44, with a turnover of HK$68.88,900.

CITIC Construction Investment's latest research report points out that the AI pharmaceutical field is undergoing rapid iteration and transformation. The updated iterations of algorithms and support for computing power have laid a good foundation for the application of AI in the pharmaceutical field. The traditional drug development process takes a long time and is expensive, and the success rate is low. As new drugs with existing targets are approved one after another, the difficulty of developing new drugs gradually increases. The development of AI in recent years, in particular deep learning, has promoted its applications including target screening, molecular generation and optimization, ADMET prediction, crystal type prediction, and synthetic route screening. It is expected to reshape the process of early drug discovery and greatly accelerate the efficiency and success rate of early drug screening.

According to the Zhitong Finance App, the core reason why Jetai Technology can lead the race is the uniqueness and leadership of its “AI for Nano”. The company's self-developed AIItem recently completed localization deployment in Hengrui Pharmaceutical, which means that AI pharmaceuticals are moving from single-point project cooperation to a new stage of platform-based export. As far as Jietai Technology is concerned, cooperation with leading domestic innovative drugs has verified the commercialization value of its AI platform. It has also made the company a scarce target for AI4S implementation scenarios, promoting the export of AI R&D platforms to more pharmaceutical companies, and speeding up the commercialization of AI pharmaceutical infrastructure.